LMAT, US5255582018

LeMaitre Vascular stock reports on November 4, 2026

Published on 10/17/2026 at 22:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LeMaitre's ratio was 28.36 on October 16, 2026. LeMaitre Vascular stock was USD 80.82 on October 16, down 2.81 percent versus Nasdaq's prior close.

Scheduled results and valuation

LeMaitre Vascular will publish third-quarter results on November 4, 2026.
Its price-to-earnings ratio was 28.36 on October 16, 2026.
LeMaitre Vascular stock last stood at USD 80.82 on Nasdaq on October 16, 2026, down 2.81 percent versus the prior close.
Market capitalization was USD 1.8 billion on October 16, 2026.

LMAT, US5255582018, Illustration mit AI erstellt.

LeMaitre Vascular will release its third-quarter 2026 financial results on November 4, 2026, after the market close, according to an October 12, 2026 release carried by GlobeNewswire. The Nasdaq-listed medical-device company last stood at USD 80.82 on October 16, 2026 at 4:00 p.m. ET, down 2.81 percent versus the Nasdaq prior close of USD 83.16.

Price sits above yearly low

LeMaitre Vascular's 52-week range was USD 78.22 to USD 118.01 as of October 16, 2026. At USD 80.82, the stock was 3.32 percent above its yearly low and 31.51 percent below its yearly high. The session volume was 311,545 shares, compared with an average of 328,196 shares.

Valuation stays measurable

The company had a market capitalization of USD 1.8 billion and a price-to-earnings ratio of 28.36 on October 16, 2026. The next scheduled company date is November 4, 2026, when LeMaitre is due to discuss third-quarter results and its outlook after the market close, as stated by GlobeNewswire.

Comparison with peers

LeMaitre Vascular (Nasdaq, USD): minus 2.81 percent, P/E 28.36, market capitalization USD 1.8 billion

Edwards Lifesciences (NYSE, USD): minus 1.70 percent, P/E 49.77, market capitalization USD 49.9 billion

Integer Holdings (NYSE, USD): minus 0.02 percent, P/E 34.62, market capitalization USD 4.3 billion

November date sets the next marker

The November 4 release is the next concrete calendar marker for LeMaitre Vascular. The company develops medical devices, implants and services for peripheral vascular disease, including disposable and implantable products for vascular surgeons.

Stock position after Nasdaq close

LeMaitre Vascular's valuation remains tied to a USD 1.8 billion market capitalization and a price-to-earnings ratio of 28.36. Its next results date gives investors a defined point for reassessing revenue, earnings and the company's outlook.

Market context: Market report Nasdaq Composite.

More news and analyses on LeMaitre Vascular stock